Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies

Scabies Clinical Trial

Official title:

A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% (Encube Ethicals) Compared to Elimite™ Cream (Permethrin) 5% (Prestium Pharma, Inc.) in the Treatment of Scabies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03178942
• Other study ID #: 71675502
• Status: Completed
• Phase: Phase 3
• Start date: June 1, 2017
• Est. completion date: November 11, 2017

Study information

• Verified date: February 2019
• Source: Encube Ethicals Pvt. Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study to Evaluate the Therapeutic Equivalence of Permethrin Cream 5%in the Treatment of Scabies.

Description:

A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream 5% (Encube Ethicals) Compared to Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.) in the Treatment of Scabies.

The objectives of this study are to:

1. Evaluate the therapeutic equivalence of the Test formulation, Permethrin Cream, 5% (Encube Ethicals) to the marketed product, Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.) in patients with scabies.

2. Compare the safety of Test and Reference treatments in patients with scabies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 254
• Est. completion date: November 11, 2017
• Est. primary completion date: November 11, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

1. Male or non-pregnant, non-lactating female, 2 years of age or older.

2. If female and of childbearing potential, prepared to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., double barrier methods, intrauterine device (IUD), oral, transdermal or injected hormonal contraceptives). Female patients using hormonal contraceptives should have been on the same product/dosing regimen for at least 28 days before baseline and should not change this regimen during the study.

3. Signed informed consent that meets all criteria of current FDA and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) regulations. For patients who are considered minors in the state the study is being conducted (< 18 years in most states) the parent or legal guardian should sign the consent form and the child will be required to sign a patient "assent" form, as appropriate. Patients 11-17 years of age will read and sign an Independent Review Board (IRB)-approved assent form and patients 6-10 years of age will provide verbal assent. Patients 2-5 years of age will be exempt from providing assent based on the child's comprehension and cognitive skills.

4. Clinical diagnosis of active scabies by presence of a burrow and/or typical scabietic lesions at the classic sites of infestation.

5. Parasitological confirmation of clinical diagnosis with demonstration under light microscope of mites and/or their products (larvae, eggs or fecal material).

6. Symptom score of 2 or 3 on a 4-point rating scale of 0-3 for nocturnal itching/pruritus.

7. Ability to apply or have study product applied as directed. If patient is a child, then parent/guardian will apply study product to him/her.

Exclusion Criteria:

1. Patients who are pregnant, lactating, or planning to become pregnant during the study.

2. Any systemic or dermatologic disorder that, in the opinion of the Investigator, will interfere with the study results or increase the risk of adverse events (AEs).

3. Known hypersensitivity to permethrin cream or any of its components.

4. Use of any systemic or topical acaricide or ectoparasiticide within one month before Screening.

5. Patient has signs of a systemic infection or is receiving systemic therapy for an infectious disease.

6. Patients with severe cutaneous bacterial or fungal infections requiring therapy (including systemic and topical antibiotics) or coexisting dermatological disorder that could interfere with the diagnosis and subsequent monitoring of scabies) or heavily crusted with lesions consistent with Norwegian scabies.

7. Patients with an underlying immunodeficient state (including prolonged treatment with corticosteroids), immunosuppressive disorders requiring therapy, severe systemic disease and history of HIV infection.

8. Any condition, medical, psychological, or social, that, in the Investigator's opinion, would interfere with participation in the study.

9. Family members of employees of the clinic or Investigator.

10. Patients who, in the opinion of the Investigator, would be non-compliant with the requirements of the study protocol.

11. Patients whose close personal contacts will not or are not willing to comply with standard of care for Scabies management.

12. Receipt of any drug as part of a research study within 30 days before Screening.

13. History of seizures.

14. Use of systemic corticosteroids within two weeks before Screening.

15. Use of topical corticosteroids within one week before Screening.

16. Previous participation in this study.

Related Conditions & MeSH terms

• Scabies

Intervention

Drug:
• Permethrin Cream, 5%
Permethrin Cream 5%
• Elimite™ Cream (permethrin) 5%
Permethrin Cream 5%

Locations

Country	Name	City	State
El Salvador	Clinica de la Doctora Laura Vargas	San Salvador
El Salvador	Clinica Dermatologica Y Cirugia de Piel/APF Research International	San Salvador
El Salvador	Clinica Dermatologica/APF Research International	San Salvador
Puerto Rico	APF Research International	Aguas Buenas
Puerto Rico	APF Research International	Loiza
United States	St. Josephs Clinical Research	Anaheim	California
United States	DermDox Cetners for Dermatology	Hazleton	Pennsylvania
United States	Integrity Clinical Research Center, Inc.	Hialeah	Florida
United States	West Houston Clinical Research Services	Houston	Texas
United States	The Chappel Group Research	Kissimmee	Florida
United States	Applied Research Center of Arkansas	Little Rock	Arkansas
United States	Long Beach Clinical Trials	Long Beach	California
United States	Havana Research Institute	Pasadena	California
United States	Sun Research Instiute	San Antonio	Texas
United States	Lenus Research & Medical Group, LLC	Sweetwater	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Encube Ethicals Pvt. Ltd.	Novum Pharmaceutical Research Services

Countries where clinical trial is conducted

United States,  El Salvador,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Patients With a Therapeutic Cure That Completed Visit 2 Within 14 ± 2 Days and Visit 3 Within 28 ± 4 Days.	Parasitological cure is defined as failure to demonstrate microscopically the presence of scabies infestation (i.e., no living mites, no viable mite eggs, and no mite fecal matter present).; Clinical cure is defined as visual evidence of absence of new lesions and healing of original lesions, regardless the presence of post-scabietic nodules (i.e., post-scabietic nodules need not be considered as new lesions or persistence of old lesions).	Visit 2 Within 14 ± 2 Days and Visit 3 Within 28 ± 4 Days
Other	Number of Patients With a Therapeutic Cure That Completed Visit 2 Within 14 ± 2 Days and Visit 3 Between Day 26 and Day 32, Inclusive.	Parasitological cure is defined as failure to demonstrate microscopically the presence of scabies infestation (i.e., no living mites, no viable mite eggs, and no mite fecal matter present).; Clinical cure is defined as visual evidence of absence of new lesions and healing of original lesions, regardless the presence of post-scabietic nodules (i.e., post-scabietic nodules need not be considered as new lesions or persistence of old lesions).	Visit 2 within 14 ± 2 days and Visit 3 between Day 26 and Day 32, inclusive.
Other	Number of Patients With a Therapeutic Cure That Completed Visit 2 Within 14 ± 2 Days and Visit 3 Within 28 ± 2 Days.	Parasitological cure is defined as failure to demonstrate microscopically the presence of scabies infestation (i.e., no living mites, no viable mite eggs, and no mite fecal matter present).; Clinical cure is defined as visual evidence of absence of new lesions and healing of original lesions, regardless the presence of post-scabietic nodules (i.e., post-scabietic nodules need not be considered as new lesions or persistence of old lesions).	Visit 2 Within 14 ± 2 Days and Visit 3 Within 28 ± 2 Days
Primary	Number of Patients in Each Treatment Group With Therapeutic Cure (Parasitological Cure Plus Clinical Cure) of Scabies	Parasitological cure is defined as failure to demonstrate microscopically the presence of scabies infestation (i.e., no living mites, no viable mite eggs, and no mite fecal matter present).; Clinical cure is defined as visual evidence of absence of new lesions and healing of original lesions, regardless the presence of post-scabietic nodules (i.e., post-scabietic nodules need not be considered as new lesions or persistence of old lesions).	Day 28 ± 4